Public Health Seminar. HPV Vaccine Implementation in Developing Countries
(1/27/2014) 67 minutes


There are more than 525,000 new cases of and over 265,000 new deaths from cervical cancer each year, with 85% of the disease burden occurring in developing countries. Screening programs have had limited success in low-resource settings due to the high cost and technology requirements for large-scale, effective call-recall approaches. Highly efficacious HPV vaccines provide an excellent opportunity for cervical cancer prevention in developing countries by catalyzing the existing infrastructure and experience of national immunization programs to deliver this vaccine to young adolescent girls leveraging their proven achievement in delivering lifesaving vaccines to infants and others. This seminar will summarize the global experience from more than30 low- and middle-income countries for the delivery of HPV vaccines to young adolescent girls. Utilizing available data from the published literature, common features of successful programs will be described and recommendations for overcoming challenges for vaccine acceptability or feasibility will be reviewed. As vaccine price was previously a formidable barrier to widespread use of HPV vaccines in developing countries, the current global environment for HPV vaccine costs and financing will be presented. The collective experience to-date suggests components of a strong foundation for successful HPV vaccine implementation that can be modeled by countries planning to introduce this vaccine into their national immunization programs.

more on this subject: